Mirati Therapeutics

7 Billion-Dollar Oncology M&As from Q1
BioSpace
Wed, 04/10/24 - 11:24 am
oncology
M&A
AbbVie
Immunogen
Bristol Myers Squibb
Mirati Therapeutics
RayzeBio
Novartis
MorphoSys
AstraZeneca
Fusion Pharmaceuticals
JNJ
Ambrx
Gracell
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
CP Wire/Businesswire
Sun, 10/8/23 - 06:16 pm
Bristol Myers Squibb
M&A
Mirati Therapeutics
oncology
cancer
Krazati
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Tue, 10/10/23 - 05:29 pm
Bristol Myers Squibb
M&A
Mirati Therapeutics
oncology
Sanofi weighs Mirati buy as KRAS cancer drug battle enters new phase
Fierce Pharma
Thu, 10/5/23 - 09:10 pm
Mirati Therapeutics
Sanofi
M&A
KRAS inhibitors
Mirati’s Krazati remains effective in two-year follow-up of NSCLC patients
Clinical Trials Arena
Mon, 09/11/23 - 12:29 pm
Mirati Therapeutics
non-small cell lung cancer
Krazati
clinical trials
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
BioSpace
Wed, 08/9/23 - 11:55 am
Mirati Therapeutics
Pharma CEOs
David Meek
Amgen
KRAS inhibitors
Mirati's flagship KRAS inhibitor Krazati gets rebuffed in Europe
Fierce Pharma
Sun, 07/23/23 - 12:38 pm
Mirati Therapeutics
Europe
Krazati
Mirati's long wait for next lung cancer med ends in phase 3 failure
Fierce Biotech
Wed, 05/24/23 - 06:53 pm
Mirati Therapeutics
clinical trials
sitravantinib
lung cancer
non small cell lung cancer
Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear
Fierce Pharma
Thu, 05/11/23 - 09:07 pm
Mirati Therapeutics
Krazati
Amgen
Lumakras
lung cancer
AACR: Lilly challenges Amgen, Mirati with early KRAS data, heading for a field 'much less crowded than it seems'
Fierce Biotech
Tue, 04/18/23 - 10:18 pm
Eli Lilly
Amgen
Mirati Therapeutics
KRAS inhibitors
AACR
FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen
MedCity News
Wed, 12/14/22 - 10:19 am
Amgen
Mirati Therapeutics
Krazati
Lumakras
FDA
lung cancer
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Yahoo/Reuters
Tue, 12/6/22 - 10:21 am
Mirati Therapeutics
adagrasib
Merck
Keytruda
metastatic lung cancer
lung cancer
Amid Buyout Buzz, Mirati Pushes Phase III NSCLC Study to Final Analysis
BioSpace
Sun, 12/4/22 - 01:17 pm
Mirati Therapeutics
clinical trials
M&A
non-small cell lung cancer
sitravantinib
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
Mirati is once again the subject of Big Pharma takeover talks: report
Fierce Biotech
Sun, 11/27/22 - 07:08 pm
Mirati Therapeutics
M&A
Amgen
Lumakras
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
Wed, 10/12/22 - 11:03 am
FDA
Biogen
Eisai
Alzheimer's disease
Gilead Sciences
HIV
Mirati Therapeutics
lung cancer
lecanemab
lenacapavir
adagrasib
ESMO 2022 movers – KRAS backfires
EP Vantage
Thu, 09/15/22 - 10:12 am
ESMO
KRAS inhibitors
Relay Therapeutics
Regeneron
Amgen
Deciphera
Clovis Oncology
Ayala Pharmaceuticals
Springworks
Mirati Therapeutics
Brace for an end-of-year boost to drug approvals
EP Vantage
Fri, 09/2/22 - 12:14 pm
FDA
drug approvals
Alnylam Pharmaceuticals
Apellis Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
Mirati Therapeutics
Moderna Therapeutics
Provention Bio
Roche
TG Therapeutics
Travere Therapeutics
ASCO: It's all tied up? Mirati's KRAS data are 'identical' to Amgen's, researcher says
Fierce Biotech
Mon, 06/6/22 - 10:33 am
ASCO 2022
Mirati Therapeutics
Amgen
Lumakras
adagrasib
lung cancer
Mirati matches Amgen with updated data for KRAS-blocking cancer drug
BioPharma Dive
Fri, 05/27/22 - 10:15 am
Mirati Therapeutics
Amgen
KRAS
adagrasib
Lumakras
clinical trials

Pages